$URG
UR-ENERGY INC

2024 Q1 Form 10-K Financial Statement

#000165495424002673 Filed on March 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $5.441M $17.68M
YoY Change -100.0% 92947.37%
Cost Of Revenue $1.139M $5.055M $19.37M
YoY Change -82.49% 177.44% 182.25%
Gross Profit -$1.139M $386.0K -$1.686M
YoY Change 1898.25% -121.19% -75.36%
Gross Profit Margin 7.09% -9.54%
Selling, General & Admin $2.569M $1.416M $6.154M
YoY Change 80.66% 11.85% 1.94%
% of Gross Profit 366.84%
Research & Development $12.46M $7.241M $22.51M
YoY Change 719.41% 281.71% 248.64%
% of Gross Profit 1875.91%
Depreciation & Amortization $603.0K $611.0K $2.167M
YoY Change 27.48% -14.78% 22.57%
% of Gross Profit 158.29%
Operating Expenses $15.15M $8.783M $29.16M
YoY Change 394.13% 167.45% 125.11%
Operating Profit -$16.28M -$8.397M -$30.84M
YoY Change 421.59% 64.45% 55.81%
Interest Expense -$2.256M $2.951M $210.0K
YoY Change -193.38% 1368.16% -54.64%
% of Operating Profit
Other Income/Expense, Net -$1.000K -$26.00K -$24.00K
YoY Change -85.71% -425.0% -101.91%
Pretax Income -$18.54M -$5.472M -$30.72M
YoY Change 2500.42% 11.74% 79.46%
Income Tax
% Of Pretax Income
Net Earnings -$18.54M -$5.472M -$30.66M
YoY Change 2500.42% 11.74% 78.86%
Net Earnings / Revenue -100.57% -173.4%
Basic Earnings Per Share -$0.07 -$0.12
Diluted Earnings Per Share -$0.07 -$0.02 -$0.12
COMMON SHARES
Basic Shares Outstanding 281.6M shares 266.0M shares 260.0M shares
Diluted Shares Outstanding 278.0M shares 260.0M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.90M $59.70M $59.70M
YoY Change -30.26% 80.89% 80.89%
Cash & Equivalents $53.90M $59.70M $48.19M
Short-Term Investments
Other Short-Term Assets $1.347M $1.321M $1.321M
YoY Change 12.44% 28.25% 28.25%
Inventory $4.698M $2.571M $2.571M
Prepaid Expenses $1.347M $1.321M
Receivables
Other Receivables
Total Short-Term Assets $60.02M $63.67M $63.67M
YoY Change -29.19% 44.89% 44.89%
LONG-TERM ASSETS
Property, Plant & Equipment $21.15M $21.04M $55.95M
YoY Change 2.32% 4.53% 0.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.641M $8.549M $8.549M
YoY Change 5.08% 5.06% 5.06%
Total Long-Term Assets $64.92M $64.71M $64.71M
YoY Change 0.97% 1.18% 1.18%
TOTAL ASSETS
Total Short-Term Assets $60.02M $63.67M $63.67M
Total Long-Term Assets $64.92M $64.71M $64.71M
Total Assets $124.9M $128.4M $128.4M
YoY Change -16.18% 18.98% 18.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.663M $1.680M $1.680M
YoY Change 224.45% 154.55% 154.55%
Accrued Expenses $1.411M $917.0K $917.0K
YoY Change 76.82% 58.93% 58.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $5.694M $5.694M
YoY Change -100.0% 6.11% 6.11%
Total Short-Term Liabilities $5.074M $10.03M $10.03M
YoY Change -42.35% 51.96% 51.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $42.92M $43.47M $43.47M
YoY Change 9.79% 31.4% 31.4%
Total Long-Term Liabilities $42.92M $43.47M $43.47M
YoY Change -1.78% 12.06% 12.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.074M $10.03M $10.03M
Total Long-Term Liabilities $42.92M $43.47M $43.47M
Total Liabilities $47.99M $53.51M $53.51M
YoY Change -8.59% 17.87% 17.87%
SHAREHOLDERS EQUITY
Retained Earnings -$269.5M -$250.9M
YoY Change 21.94% 13.92%
Common Stock $322.2M $302.2M
YoY Change 9.74% 16.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $76.95M $74.87M $74.87M
YoY Change
Total Liabilities & Shareholders Equity $124.9M $128.4M $128.4M
YoY Change -16.18% 18.98% 18.98%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$18.54M -$5.472M -$30.66M
YoY Change 2500.42% 11.74% 78.86%
Depreciation, Depletion And Amortization $603.0K $611.0K $2.167M
YoY Change 27.48% -14.78% 22.57%
Cash From Operating Activities -$14.38M -$322.0K -$16.98M
YoY Change -717.83% -94.4% -6.13%
INVESTING ACTIVITIES
Capital Expenditures $843.0K $119.0K $2.039M
YoY Change 26.77% -76.01% 187.59%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$843.0K -$119.0K -$2.039M
YoY Change 26.77% -76.01% 187.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $53.14M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $9.556M 5.585M $46.09M
YoY Change -77.62% -1006.66% 682.03%
NET CHANGE
Cash From Operating Activities -$14.38M -322.0K -$16.98M
Cash From Investing Activities -$843.0K -119.0K -$2.039M
Cash From Financing Activities $9.556M 5.585M $46.09M
Net Change In Cash -$5.712M 5.144M $27.11M
YoY Change -112.88% -174.91% -308.29%
FREE CASH FLOW
Cash From Operating Activities -$14.38M -$322.0K -$16.98M
Capital Expenditures $843.0K $119.0K $2.039M
Free Cash Flow -$15.22M -$441.0K -$19.02M
YoY Change -1015.76% -92.95% 1.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Revenues
Revenues
16000 usd
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
7000000 usd
CY2021 us-gaap Gross Profit
GrossProfit
-6984000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
9773000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-16757000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-22938000 usd
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
435000 usd
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22503000 usd
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
195691842 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
195691842 shares
CY2023 urg Restricted Stock Units Redeemed For Cash
RestrictedStockUnitsRedeemedForCash
69000 usd
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001375205
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q3 us-gaap Mineral Properties Net
MineralPropertiesNet
34892000 usd
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEnding
8574904 shares
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEnding
10064024 shares
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding
0.66
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEnding
0.68
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueEnding
1.14
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Ending
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueEnding
0.69
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
270898900 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
224699621 shares
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-33905
CY2023 dei Entity Registrant Name
EntityRegistrantName
UR-ENERGY INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
10758 West Centennial Road
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Littleton
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80127
CY2023 dei City Area Code
CityAreaCode
720
CY2023 dei Local Phone Number
LocalPhoneNumber
981-4588
CY2023 dei Security12b Title
Security12bTitle
Common Shares, no par value
CY2023 dei Trading Symbol
TradingSymbol
URG
CY2023 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
281626324 shares
CY2023Q2 dei Entity Public Float
EntityPublicFloat
252300000 usd
CY2023 dei Auditor Firm
AuditorFirmId
271
CY2023 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2023 dei Auditor Location
AuditorLocation
Vancouver, Canada
CY2023Q4 us-gaap Notes Payable
NotesPayable
0 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
5694000 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-733000 usd
CY2021 urg Warrant Liability Revaluation Gain Loss
WarrantLiabilityRevaluationGainLoss
-5998000 usd
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-355000 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
905000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
34096000 usd
CY2021 urg Shares Issued For Cash Amount
SharesIssuedForCashAmount
46068000 usd
CY2021 urg Less Share Issue Costs
LessShareIssueCosts
-2188000 usd
CY2021 urg Exercise Of Warrants Amount
ExerciseOfWarrantsAmount
11337000 usd
CY2021 urg Exercise Of Stock Options Amount
ExerciseOfStockOptionsAmount
1785000 usd
CY2021 urg Redemption Of Rsus Amount
RedemptionOfRsusAmount
-288000 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1079000 usd
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22503000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69386000 usd
CY2022 urg Shares Issued For Cash Amount
SharesIssuedForCashAmount
3775000 usd
CY2022 urg Less Share Issue Costs
LessShareIssueCosts
-94000 usd
CY2022 urg Exercise Of Warrants Amount
ExerciseOfWarrantsAmount
4654000 usd
CY2022 urg Exercise Of Stock Options Amount
ExerciseOfStockOptionsAmount
858000 usd
CY2022 urg Redemption Of Rsus Amount
RedemptionOfRsusAmount
-205000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1142000 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17017000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
62499000 usd
CY2023 urg Shares Issued For Cash Amount
SharesIssuedForCashAmount
44033000 usd
CY2023 urg Less Share Issue Costs
LessShareIssueCosts
-3165000 usd
CY2023 urg Exercise Of Warrants Amount
ExerciseOfWarrantsAmount
337000 usd
CY2023 urg Exercise Of Stock Options Amount
ExerciseOfStockOptionsAmount
1412000 usd
CY2023 urg Redemption Of Rsus Amount
RedemptionOfRsusAmount
-69000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1026000 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31203000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
74870000 usd
CY2021 us-gaap Profit Loss
ProfitLoss
22938000 usd
CY2021 urg Stock Based Compensation
StockBasedCompensation
1080000 usd
CY2021 urg Net Realizable Value Adjustments
NetRealizableValueAdjustments
7000000 usd
CY2021 urg Amortization Of Mineral Properties
AmortizationOfMineralProperties
2045000 usd
CY2021 us-gaap Depreciation
Depreciation
1789000 usd
CY2021 us-gaap Accretion Expense
AccretionExpense
486000 usd
CY2021 us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
46000 usd
CY2023 urg Gain On Loan Forgiveness
GainOnLoanForgiveness
0 usd
CY2022 urg Gain On Loan Forgiveness
GainOnLoanForgiveness
0 usd
CY2021 urg Gain On Loan Forgiveness
GainOnLoanForgiveness
903000 usd
CY2021 urg Provision For Reclamation
ProvisionForReclamation
5000 usd
CY2021 urg Mark To Market Loss Gain
MarkToMarketLossGain
-5998000 usd
CY2023 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 usd
CY2022 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-67000 usd
CY2021 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 usd
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-353000 usd
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
0 usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7109000 usd
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
84000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
544000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11698000 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1190000 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1190000 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48841000 usd
CY2021 urg Share Issue Costs
ShareIssueCosts
2188000 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8507000 usd
CY2022 urg Restricted Stock Units Redeemed For Cash
RestrictedStockUnitsRedeemedForCash
205000 usd
CY2021 urg Restricted Stock Units Redeemed For Cash
RestrictedStockUnitsRedeemedForCash
289000 usd
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54871000 usd
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42028000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12127000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54155000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
8549000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
8137000 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The most significant estimates management makes in the preparation of these consolidated financial statements relate to the fair value of stock-based compensation and warrant liabilities using the factors associated with the Black-Scholes calculations, estimation of the amount of recoverable uranium included in the in-process inventory, estimation of factors surrounding asset retirement obligations such as interest rates, discount rates and inflation rates, total cost and the time until the asset retirement commences and the offset of future income taxes through deferred tax assets. Actual results could differ from those estimates.</p>
CY2023 urg Mineralpropertiespolicy Textblock
MineralpropertiespolicyTextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Acquisition costs of mineral properties are capitalized. Amortization is calculated on a straight-line basis. The estimated life for the Lost Creek Project was 10 years which was used to amortize the mineral property acquisition costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">If properties are abandoned or sold, they are written off. If properties are impaired in value, the costs of the properties are written down to their estimated fair value at that time.</p>
CY2023 urg Capital Assets Policy Textblock
CapitalAssetsPolicyTextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Property, plant, and equipment assets, including machinery, processing equipment, enclosures, and vehicles are recorded at cost including acquisition, installation costs, and expenditures that extend the life of such assets. The enclosure costs include both the building enclosure and the processing equipment necessary for the extraction of uranium from impregnated water pumped in from the wellfield to the packaging of uranium yellowcake for delivery into sales. These enclosure costs are combined as the equipment and related installation associated with the equipment is an integral part of the structure itself.<em> </em>The costs of self-constructed assets include direct construction costs, direct overhead, and allocated interest during the construction phase. Depreciation is calculated using a declining balance method for most assets, except the plant enclosure and related equipment. Depreciation of the plant enclosure and related equipment is calculated on a straight-line basis. Estimated lives for depreciation purposes range from three years for computer equipment and software to 20 years for the plant enclosure and the nameplate life of the related equipment.</p>
CY2023 urg Right Of Use Assets And Liabilities Policy Textblock
RightOfUseAssetsAndLiabilitiesPolicyTextblock
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Right of use assets include storage facility and office equipment leases. We recognize an asset and corresponding liability, which are included in non-current assets and other liabilities in the consolidated balance sheet, based on the present value of the remaining minimum rental payments of the leases. The discount rates used are based on either the Company’s borrowing rate or the imputed interest rate based on the price of the equipment and the lease terms.</p>
CY2023 us-gaap Revenue Recognition Leases
RevenueRecognitionLeases
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Our revenues are primarily derived from the sale of U<sub style="vertical-align:sub">3</sub>O<sub style="vertical-align:sub">8</sub> under either long-term (deliveries typically in two to five years) or spot (immediate delivery) contracts with our customers. The contracts specify the quantity to be delivered, the price or specific calculation method of the price, payment terms, and the year(s) of the delivery. When a delivery is approved, the Company notifies the conversion facility with instructions for a title transfer to the customer. Revenue is recognized once a title transfer of the U<sub style="vertical-align:sub">3</sub>O<sub style="vertical-align:sub">8</sub> is confirmed by the conversion facility.</p>
CY2022Q4 us-gaap Other Restricted Assets
OtherRestrictedAssets
20000 usd
CY2023Q4 us-gaap Cash
Cash
11515000 usd
CY2022Q4 us-gaap Cash
Cash
2560000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
48185000 usd
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
30443000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59700000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33003000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9903000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2571000 usd
CY2023 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
10689000 usd
CY2022 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
6861000 usd
CY2023Q4 urg Cash Pledged For Reclamation
CashPledgedForReclamation
8518000 usd
CY2022Q4 urg Cash Pledged For Reclamation
CashPledgedForReclamation
8117000 usd
CY2023Q4 us-gaap Other Restricted Assets
OtherRestrictedAssets
31000 usd
CY2020Q4 us-gaap Mineral Properties Net
MineralPropertiesNet
39184000 usd
CY2021 urg Reclassify Assetsheld For Sale
ReclassifyAssetsheldForSale
-1536000 usd
CY2021 urg Change In Estimated Reclamation Costs
ChangeInEstimatedReclamationCosts
-536000 usd
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
-2045000 usd
CY2021Q4 us-gaap Mineral Properties Net
MineralPropertiesNet
35067000 usd
CY2022 urg Reclassify Assetsheld For Sale
ReclassifyAssetsheldForSale
1536000 usd
CY2022 urg Change In Estimated Reclamation Costs
ChangeInEstimatedReclamationCosts
326000 usd
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
-1247000 usd
CY2022Q4 us-gaap Mineral Properties Net
MineralPropertiesNet
35682000 usd
CY2023 urg Change In Estimated Reclamation Costs
ChangeInEstimatedReclamationCosts
38000 usd
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
-814000 usd
CY2023Q4 us-gaap Mineral Properties Net
MineralPropertiesNet
34906000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43909000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22865000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21044000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
40936000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20804000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20132000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1680000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
660000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
578000 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
449000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
108000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
59000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2366000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1168000 usd
CY2023Q4 us-gaap Debt Current
DebtCurrent
5727000 usd
CY2022Q4 us-gaap Debt Current
DebtCurrent
5409000 usd
CY2023Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
33000 usd
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
43000 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
5694000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
5366000 usd
CY2023Q4 urg Long Term Debt Noncurrent Gross
LongTermDebtNoncurrentGross
0 usd
CY2022Q4 urg Long Term Debt Noncurrent Gross
LongTermDebtNoncurrentGross
5727000 usd
CY2023Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 usd
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
33000 usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
0 usd
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
5694000 usd
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2144000 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2604000 usd
CY2021 urg Adjustments To Additional Paid In Capital Warrant Exercise
AdjustmentsToAdditionalPaidInCapitalWarrantExercise
-4446000 usd
CY2021 urg Mark To Market Revaluation Loss Gain
MarkToMarketRevaluationLossGain
5998000 usd
CY2021 urg Effects For Foreign Exchange Rate Changes
EffectsForForeignExchangeRateChanges
-37000 usd
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6263000 usd
CY2022 urg Adjustments To Additional Paid In Capital Warrant Exercise
AdjustmentsToAdditionalPaidInCapitalWarrantExercise
-1790000 usd
CY2022 urg Mark To Market Revaluation Loss Gain
MarkToMarketRevaluationLossGain
-1835000 usd
CY2022 urg Effects For Foreign Exchange Rate Changes
EffectsForForeignExchangeRateChanges
-256000 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2382000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9109000 usd
CY2023 urg Adjustments To Additional Paid In Capital Warrant Exercise
AdjustmentsToAdditionalPaidInCapitalWarrantExercise
-58000 usd
CY2023 urg Mark To Market Revaluation Loss Gain
MarkToMarketRevaluationLossGain
1586000 usd
CY2023 urg Effects For Foreign Exchange Rate Changes
EffectsForForeignExchangeRateChanges
273000 usd
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
13292000 usd
CY2023Q4 urg Current Portion Of Warrant Liability
CurrentPortionOfWarrantLiability
1743000 usd
CY2023Q4 urg Warrant Liability
WarrantLiability
11549000 usd
CY2023Q4 urg Warrant Laibility
WarrantLaibility
13292000 usd
CY2020Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
29965000 usd
CY2021 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
-536000 usd
CY2021 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
486000 usd
CY2021Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
29915000 usd
CY2022 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
326000 usd
CY2022 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
460000 usd
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
30701000 usd
CY2023 us-gaap Asset Retirement Obligation Revision Of Estimate
AssetRetirementObligationRevisionOfEstimate
38000 usd
CY2023 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
497000 usd
CY2023Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
31236000 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
224699621 shares
CY2021Q1 urg Shares Issued Upon Public Offering
SharesIssuedUponPublicOffering
14722200 shares
CY2021Q1 urg Warrants To Purchase Shares
WarrantsToPurchaseShares
7361100 shares
CY2021Q1 us-gaap Accelerated Share Repurchases Initial Price Paid Per Share
AcceleratedShareRepurchasesInitialPricePaidPerShare
0.90
CY2021Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2208330 shares
CY2021Q1 us-gaap Investment Sold Not Yet Purchased Balance Shares
InvestmentSoldNotYetPurchasedBalanceShares
1104165 shares
CY2021Q1 urg Proceeds From Warrant Exercises One
ProceedsFromWarrantExercisesOne
15200000 usd
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
1300000 usd
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13900000 usd
CY2021Q1 urg Class Of Warrant Or Right Exercise Price Of Warrants
ClassOfWarrantOrRightExercisePriceOfWarrants
1.35
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginning
11910424 shares
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning
0.61
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1322164 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.14
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
2929101 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.62
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
219055 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.56
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
20408 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.57
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginning
10064024 shares
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginning
0.68
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
175000 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.74
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
1308625 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.66
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
355495 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.66
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2607657 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.32
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.64
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
39999 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.13
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
17129 shares
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.68
CY2022 urg Number Of Stock Options Exercised
NumberOfStockOptionsExercised
900000 usd
CY2021 urg Number Of Stock Options Exercised
NumberOfStockOptionsExercised
1800000 usd
CY2022 urg Sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpected Forfeiture Rate
SharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedForfeitureRate
0.056 pure
CY2021 urg Sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpected Forfeiture Rate
SharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedForfeitureRate
0.061 pure
CY2023 urg Expected Life Years
ExpectedLifeYears
P4Y
CY2022 urg Expected Life Years
ExpectedLifeYears
P3Y10M24D
CY2021 urg Expected Life Years
ExpectedLifeYears
P3Y10M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.727 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.695 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.007 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022 urg Weighted Average Exercise Price
WeightedAverageExercisePrice
2.23
CY2021 urg Weighted Average Exercise Price
WeightedAverageExercisePrice
1.44
CY2022 urg Black Scholes Value Cad
BlackScholesValueCad
1.22
CY2021 urg Black Scholes Value Cad
BlackScholesValueCad
0.74
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1404962 shares
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueBeginning
0.54
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriod
305530 shares
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValue
1.14
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
-638989 shares
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue
0.63
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
59843 shares
CY2021 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Grant Date Forfeited Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateForfeitedFairValue
0.56
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1011660 shares
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Beginning
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueBeginning
0.69
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
-706130 shares
CY2022 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue
0.47
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
305530 shares
CY2023 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriod
651912 shares
CY2023 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateFairValue
1.32
CY2023 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
-312575 shares
CY2023 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue
1.14
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
2957 shares
CY2023 urg Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Grant Date Forfeited Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageGrantDateForfeitedFairValue
1.15
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22062878 shares
CY2020Q4 urg Class Of Warrants Or Right Shares Issued On Exercise
ClassOfWarrantsOrRightSharesIssuedOnExercise
11031439 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.90
CY2021 urg Number Of Warrants Issued
NumberOfWarrantsIssued
16930530 shares
CY2021 urg Number Of Shares To Be Issued Upon Exercise Issued
NumberOfSharesToBeIssuedUponExerciseIssued
8465265 shares
CY2021 urg Per Share Exercise Price Issued
PerShareExercisePriceIssued
1.35
CY2021 urg Number Of Warrants Exercised
NumberOfWarrantsExercised
-14050920 shares
CY2021 urg Number Of Shares To Be Issued Upon Exercise Exercised
NumberOfSharesToBeIssuedUponExerciseExercised
-7025460 shares
CY2021 urg Per Share Exercise Price Exercised
PerShareExercisePriceExercised
0.98
CY2021 urg Number Of Warrants Expired
NumberOfWarrantsExpired
-573958 shares
CY2021 urg Number Of Shares To Be Issued Upon Exercise Expired
NumberOfSharesToBeIssuedUponExerciseExpired
-286979 shares
CY2021 urg Per Share Exercise Price Expired
PerShareExercisePriceExpired
1.00
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
24368530 shares
CY2021Q4 urg Class Of Warrants Or Right Shares Issued On Exercise
ClassOfWarrantsOrRightSharesIssuedOnExercise
12184265 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.16
CY2022 urg Number Of Warrants Exercised
NumberOfWarrantsExercised
-7638000 shares
CY2022 urg Number Of Shares To Be Issued Upon Exercise Exercised
NumberOfSharesToBeIssuedUponExerciseExercised
-3819000 shares
CY2022 urg Per Share Exercise Price Exercised
PerShareExercisePriceExercised
0.75
CY2023 urg Number Of Warrants Issued
NumberOfWarrantsIssued
39100000 shares
CY2023 urg Number Of Shares To Be Issued Upon Exercise Issued
NumberOfSharesToBeIssuedUponExerciseIssued
19550000 shares
CY2023 urg Per Share Exercise Price Issued
PerShareExercisePriceIssued
1.50
CY2023 us-gaap Revenues
Revenues
17679000 usd
CY2023 urg Revenues Percentage
RevenuesPercentage
1.000 pure
CY2022 us-gaap Revenues
Revenues
19000 usd
CY2022 urg Revenues Percentage
RevenuesPercentage
1.000 pure
CY2021 us-gaap Revenues
Revenues
16000 usd
CY2021 urg Revenues Percentage
RevenuesPercentage
1.000 pure
CY2023 urg Cost Of Product Sale
CostOfProductSale
8676000 usd
CY2022 urg Cost Of Product Sale
CostOfProductSale
0 usd
CY2021 urg Cost Of Product Sale
CostOfProductSale
0 usd
CY2023 urg Lower Of Cost Or Nrv Adjustments
LowerOfCostOrNRVAdjustments
10689000 usd
CY2022 urg Lower Of Cost Or Nrv Adjustments
LowerOfCostOrNRVAdjustments
6861000 usd
CY2021 urg Lower Of Cost Or Nrv Adjustments
LowerOfCostOrNRVAdjustments
7000000 usd
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19365000 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6861000 usd
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7000000 usd
CY2023 us-gaap Exploration Expense
ExplorationExpense
2109000 usd
CY2022 us-gaap Exploration Expense
ExplorationExpense
1769000 usd
CY2021 us-gaap Exploration Expense
ExplorationExpense
2037000 usd
CY2023 us-gaap Development Costs
DevelopmentCosts
20396000 usd
CY2022 us-gaap Development Costs
DevelopmentCosts
4686000 usd
CY2021 us-gaap Development Costs
DevelopmentCosts
1922000 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6154000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6037000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5328000 usd
CY2023 us-gaap Accretion Expense
AccretionExpense
497000 usd
CY2022 us-gaap Accretion Expense
AccretionExpense
460000 usd
CY2021 us-gaap Accretion Expense
AccretionExpense
486000 usd
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
29156000 usd
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12952000 usd
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9773000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59700000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33003000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46189000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8549000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8137000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
7966000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68249000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41140000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54155000 usd
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
600000 usd
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
700000 usd
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
800000 usd
CY2023 urg Summaryofprovisionforincometaxestable Textblock
SummaryofprovisionforincometaxestableTextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="11" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended December 31,</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Income (Loss) before Income Tax Provision</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">United States</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,063</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,638</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,438</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Canada</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,659</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,481</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,470</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(30,722</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(17,119</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(22,908</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></tbody></table>
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-30722000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17119000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-22908000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
14377000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
13243000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
12841000 usd
CY2023Q4 urg Deferred Tax Assets Operating Loss Carryforwards Noncurrent
DeferredTaxAssetsOperatingLossCarryforwardsNoncurrent
47715000 usd
CY2022Q4 urg Deferred Tax Assets Operating Loss Carryforwards Noncurrent
DeferredTaxAssetsOperatingLossCarryforwardsNoncurrent
42074000 usd
CY2021Q4 urg Deferred Tax Assets Operating Loss Carryforwards Noncurrent
DeferredTaxAssetsOperatingLossCarryforwardsNoncurrent
38800000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
62092000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55317000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51641000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62092000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55317000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51641000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6775000 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3676000 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5090000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.020 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.021 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042 pure
CY2023 urg Permanent Differences
PermanentDifferences
-0.013 pure
CY2022 urg Permanent Differences
PermanentDifferences
0.011 pure
CY2021 urg Permanent Differences
PermanentDifferences
-0.051 pure
CY2023 urg True Ups And Other
TrueUpsAndOther
-0.001 pure
CY2022 urg True Ups And Other
TrueUpsAndOther
0.002 pure
CY2021 urg True Ups And Other
TrueUpsAndOther
0.000 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.047 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.050 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.032 pure
CY2023 urg Share Issuance Costs
ShareIssuanceCosts
0.028 pure
CY2022 urg Share Issuance Costs
ShareIssuanceCosts
0.034 pure
CY2021 urg Share Issuance Costs
ShareIssuanceCosts
0.000 pure
CY2023 urg Change In Valuation Allowance
ChangeInValuationAllowance
-0.212 pure
CY2022 urg Change In Valuation Allowance
ChangeInValuationAllowance
-0.25 pure
CY2021 urg Change In Valuation Allowance
ChangeInValuationAllowance
-0.224 pure
CY2023 urg Income Tax Credits
IncomeTaxCredits
0.000 pure
CY2022 urg Income Tax Credits
IncomeTaxCredits
0.015 pure
CY2021 urg Income Tax Credits
IncomeTaxCredits
0.000 pure
CY2023 urg Income Tax Amount
IncomeTaxAmount
0.000 pure
CY2022 urg Income Tax Amount
IncomeTaxAmount
0.000 pure
CY2021 urg Income Tax Amount
IncomeTaxAmount
0.000 pure
CY2023Q4 urg Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.35
CY2023 urg Gross Proceeds From Warrant Exercises
GrossProceedsFromWarrantExercises
11100000 usd
CY2023 urg Schedule Of Lease Payments Table Textblock
ScheduleOfLeasePaymentsTableTextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lease Payments</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">280</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">139</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>989</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
285000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
285000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
280000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
139000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
989000 usd
CY2023 urg Schedule Of Principal Payments Table Textblock
ScheduleOfPrincipalPaymentsTableTextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Principal Payments</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,727</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>5,727</strong></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
5727000 usd
CY2023 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
5727000 usd
CY2023 urg Base Quantity In Next Twelve Months
BaseQuantityInNextTwelveMonths
570,000
CY2023 urg Base Quantity In Year Two
BaseQuantityInYearTwo
700,000
CY2023 urg Base Quantity In Year Three
BaseQuantityInYearThree
850,000
CY2023 urg Base Quantity In Year Four
BaseQuantityInYearFour
1,050,000
CY2023 urg Base Quantity In Year Five
BaseQuantityInYearFive
1,100,000
CY2023 urg Base Quantity In Year Six
BaseQuantityInYearSix
800,000
CY2023 urg Base Quantity In Year Seven
BaseQuantityInYearSeven
550,000
CY2023 urg Base Quantity Net
BaseQuantityNet
5,620,000
CY2023 urg Warrant Exercised
WarrantExercised
16376500 shares
CY2023Q4 urg Warrant Exercises For Underlying Whole Common Shares
WarrantExercisesForUnderlyingWholeCommonShares
8188250 shares
CY2023Q4 urg Common Stock Shares Sold
CommonStockSharesSold
2464500 shares
CY2023 urg Common Stock Shares Sold Average Price
CommonStockSharesSoldAveragePrice
1.72
CY2023 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
4200000 usd
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
600000 usd
CY2023Q4 us-gaap Foreign Currency Cash Flow Hedge Asset At Fair Value
ForeignCurrencyCashFlowHedgeAssetAtFairValue
2800000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
2400000 usd
CY2023Q4 urg Lease Liability Current
LeaseLiabilityCurrent
200000 usd
CY2023Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
5700000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
59700000 usd

Files In Submission

Name View Source Status
0001654954-24-002673-index-headers.html Edgar Link pending
0001654954-24-002673-index.html Edgar Link pending
0001654954-24-002673.txt Edgar Link pending
0001654954-24-002673-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
urg-20231231.xsd Edgar Link pending
urg_10k.htm Edgar Link pending
urg_10kimg10.jpg Edgar Link pending
urg_10kimg11.jpg Edgar Link pending
urg_10kimg2.jpg Edgar Link pending
urg_10kimg3.jpg Edgar Link pending
urg_10kimg4.jpg Edgar Link pending
urg_10kimg5.jpg Edgar Link pending
urg_10kimg6.jpg Edgar Link pending
urg_10kimg7.jpg Edgar Link pending
urg_10kimg8.jpg Edgar Link pending
urg_10kimg9.jpg Edgar Link pending
urg_ex211.htm Edgar Link pending
urg_ex211img2.jpg Edgar Link pending
urg_ex231.htm Edgar Link pending
urg_ex231img1.jpg Edgar Link pending
urg_ex232.htm Edgar Link pending
urg_ex311.htm Edgar Link pending
urg_ex312.htm Edgar Link pending
urg_ex321.htm Edgar Link pending
urg_ex322.htm Edgar Link pending
urg_ex41.htm Edgar Link pending
urg_ex961.htm Edgar Link pending
urg_ex961.pdf Edgar Link pending
urg_ex961img129.jpg Edgar Link pending
urg_ex961img133.jpg Edgar Link pending
urg_ex961img250.jpg Edgar Link pending
urg_ex961img251.jpg Edgar Link pending
urg-20231231_def.xml Edgar Link unprocessable
urg_10k_htm.xml Edgar Link completed
urg_ex961img254.jpg Edgar Link pending
urg_ex961img259.jpg Edgar Link pending
urg_ex961img260.jpg Edgar Link pending
urg_ex961img261.jpg Edgar Link pending
urg_ex961img263.jpg Edgar Link pending
urg_ex961img264.jpg Edgar Link pending
urg_ex961img265.jpg Edgar Link pending
urg_ex961img266.jpg Edgar Link pending
urg_ex961img267.jpg Edgar Link pending
urg_ex961img268.jpg Edgar Link pending
urg_ex961img269.jpg Edgar Link pending
urg_ex961img270.jpg Edgar Link pending
urg_ex961img271.jpg Edgar Link pending
urg_ex961img272.jpg Edgar Link pending
urg_ex961img273.jpg Edgar Link pending
urg_ex961img274.jpg Edgar Link pending
urg_ex961img275.jpg Edgar Link pending
urg_ex961img276.jpg Edgar Link pending
urg_ex961img277.jpg Edgar Link pending
urg_ex961img286.jpg Edgar Link pending
urg_ex961img289.jpg Edgar Link pending
urg_ex961img66.jpg Edgar Link pending
urg_ex962.htm Edgar Link pending
urg_ex962.pdf Edgar Link pending
urg_ex962img145.jpg Edgar Link pending
urg_ex962img146.jpg Edgar Link pending
urg_ex962img147.jpg Edgar Link pending
urg_ex962img149.jpg Edgar Link pending
urg_ex962img150.jpg Edgar Link pending
urg_ex962img151.jpg Edgar Link pending
urg_ex962img152.jpg Edgar Link pending
urg_ex962img153.jpg Edgar Link pending
urg_ex962img154.jpg Edgar Link pending
urg_ex962img156.jpg Edgar Link pending
urg_ex962img157.jpg Edgar Link pending
urg_ex962img158.jpg Edgar Link pending
urg_ex962img159.jpg Edgar Link pending
urg_ex962img160.jpg Edgar Link pending
urg_ex962img164.jpg Edgar Link pending
urg_ex962img165.jpg Edgar Link pending
urg_ex962img166.jpg Edgar Link pending
urg_ex962img167.jpg Edgar Link pending
urg_ex962img168.jpg Edgar Link pending
urg_ex962img169.jpg Edgar Link pending
urg_ex962img170.jpg Edgar Link pending
urg_ex962img171.jpg Edgar Link pending
urg_ex962img172.jpg Edgar Link pending
urg_ex962img173.jpg Edgar Link pending
urg_ex97.htm Edgar Link pending
urg_ex991img227.jpg Edgar Link pending
urg_ex992img120.jpg Edgar Link pending
urg_ex992img95.jpg Edgar Link pending
urg-20231231_cal.xml Edgar Link unprocessable
urg-20231231_lab.xml Edgar Link unprocessable
urg-20231231_pre.xml Edgar Link unprocessable